Capricor Therapeutics Past Earnings Performance
Past criteria checks 0/6
Capricor Therapeutics's earnings have been declining at an average annual rate of -23.4%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 71% per year.
Key information
-23.4%
Earnings growth rate
35.5%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 71.0% |
Return on equity | -98.6% |
Net Margin | -88.5% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Capricor signs intellectual property license for COVID-19 serology test platform
Feb 01Capricor and Lonza tie up in DMD development
Jan 12Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
Nov 24Revenue & Expenses BreakdownBeta
How Capricor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 25 | -22 | 13 | 0 |
30 Sep 23 | 14 | -29 | 12 | 11 |
30 Jun 23 | 9 | -29 | 12 | 0 |
31 Mar 23 | 6 | -29 | 11 | 0 |
31 Dec 22 | 3 | -29 | 10 | 0 |
30 Sep 22 | 2 | -27 | 10 | 16 |
30 Jun 22 | 0 | -25 | 9 | 0 |
31 Mar 22 | 0 | -23 | 8 | 0 |
31 Dec 21 | 0 | -20 | 8 | 0 |
30 Sep 21 | 0 | -18 | 7 | 0 |
30 Jun 21 | 0 | -18 | 6 | 0 |
31 Mar 21 | 0 | -17 | 6 | 0 |
31 Dec 20 | 0 | -14 | 6 | 0 |
30 Sep 20 | 0 | -11 | 5 | 0 |
30 Jun 20 | 1 | -9 | 5 | 0 |
31 Mar 20 | 1 | -7 | 4 | 0 |
31 Dec 19 | 1 | -8 | 4 | 0 |
30 Sep 19 | 1 | -9 | 4 | 0 |
30 Jun 19 | 2 | -12 | 4 | 0 |
31 Mar 19 | 2 | -14 | 5 | 0 |
31 Dec 18 | 2 | -15 | 5 | 0 |
30 Sep 18 | 1 | 0 | 5 | 0 |
30 Jun 18 | 2 | 2 | 5 | 0 |
31 Mar 18 | 2 | 2 | 5 | 0 |
31 Dec 17 | 3 | 2 | 5 | 0 |
30 Sep 17 | 3 | -14 | 5 | 0 |
30 Jun 17 | 4 | -17 | 5 | 0 |
31 Mar 17 | 4 | -18 | 5 | 0 |
31 Dec 16 | 4 | -19 | 5 | 0 |
30 Sep 16 | 4 | -18 | 5 | 0 |
30 Jun 16 | 5 | -15 | 5 | 0 |
31 Mar 16 | 5 | -14 | 4 | 0 |
31 Dec 15 | 6 | -13 | 4 | 0 |
30 Sep 15 | 6 | -11 | 4 | 0 |
30 Jun 15 | 6 | -10 | 4 | 0 |
31 Mar 15 | 6 | -8 | 4 | 0 |
31 Dec 14 | 5 | -6 | 3 | 0 |
30 Sep 14 | 3 | -9 | 3 | 0 |
30 Jun 14 | 2 | -9 | 3 | 0 |
31 Mar 14 | 1 | -9 | 3 | 0 |
31 Dec 13 | 1 | -9 | 2 | 0 |
30 Sep 13 | 1 | -5 | 2 | 0 |
30 Jun 13 | 2 | -4 | 2 | 0 |
Quality Earnings: CAPR is currently unprofitable.
Growing Profit Margin: CAPR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CAPR is unprofitable, and losses have increased over the past 5 years at a rate of 23.4% per year.
Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: CAPR has a negative Return on Equity (-98.61%), as it is currently unprofitable.